Our analysis of the HMF cohort indeed revealed that 32% (10/31) of ER+/HER2− breast cancer patients showed an objective response to the everolimus–exemestane combo-treatment regime (Fig. 9 A). The gene discussed is ESR1; the disease is breast cancer.